Your session is about to expire
← Back to Search
Depemokimab for Nasal Polyps (ANCHOR-1 Trial)
ANCHOR-1 Trial Summary
This trial will study if a new drug, called depemokimab, is effective and safe in people with CRSwNP.
ANCHOR-1 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowANCHOR-1 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.ANCHOR-1 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have had symptoms like nasal blockage and loss of smell for over 12 weeks.I have an immune system condition not caused by my asthma medication.I am not pregnant, breastfeeding, nor planning to become pregnant during the study.I have not had a sinus or upper respiratory infection in the last 2 weeks.I have a fungal infection in my sinuses.I have not been in a study with mepolizumab, reslizumab, or benralizumab in the last year.My doctor advises against nose surgery for me.I have antrochoanal polyps.I have severe nasal problems, including congestion, loss of smell, or a runny nose.I was hospitalized for asthma within the last month.I have had a parasitic infestation in the last 6 months.I've had nose surgery that changed the structure, affecting nasal polyp score assessments.I have a severe blockage in one nostril due to a deviated septum, making it hard to check for nasal polyps.I have a tumor in my nasal cavity.I have a condition that increases my eosinophil levels, like EGPA or Eosinophilic Esophagitis.My liver function tests are not within the normal range, and I may have serious liver issues.I have been exposed to more than 10 mSv of radiation due to work or research in the last 3 years.The doctor has checked your nose and found a score of at least 5 out of 8, with at least 2 points in each side of the nose.I do not have a current diagnosis of vasculitis.I am 18 years old or older.I have had symptoms like nasal blockage and loss of smell for over 12 weeks.I am a man or a woman eligible for this trial.I have been using nasal steroid sprays or washes daily for the last 8 weeks.I have had nasal surgery, used steroids for nasal polyps, or can't tolerate steroids.If the doctor thinks you might have COVID-19, or if you have been near someone with COVID-19 in the last 14 days, you cannot join the study. If you have lost your sense of smell or taste because of COVID-19, you cannot join the study.My cancer has been in remission for less than a year.I am currently experiencing a persistent stuffy nose due to long-term nasal spray use.I have a serious health condition that isn't managed well with treatment.I have not had any nose or sinus surgery in the last 6 months, except for a nasal biopsy.I have cystic fibrosis.I am not allergic to any components of depemokimab.
- Group 1: Participants receiving depemokimab (GSK3511294)
- Group 2: Participants receiving placebo
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the current level of approval for Depemokimab (GSK3511294)?
"Depemokimab (GSK3511294) has received a safety score of 3. This is partially because it is a Phase 3 trial, meaning that there is not just data supporting efficacy, but multiple rounds of data affirming its safety."
At how many facilities are patients being recruited for this clinical trial?
"17 trial sites are currently operational. They are situated in Meridian, Tampa, New Brunswick and other locations. To cut down on travel for participants, it is best to select the closest site."
What goals does this trial hope to achieve?
"The purpose of this study is to see if the medication has an effect on reducing the size of nasal polyps. This will be measured by looking at the change in total endoscopic Nasal polyps (NP) score from Baseline to Week 52. Additionally, we will also look at secondary outcomes including the change in mean nasal obstruction score using VRS from Weeks 21 to 24 and the change in mean symptom score for loss of smell using VRS. The study will also assess participants' Asthma Control Questionnaire-5 (ACQ-5) scores to determine impact on asthma control."
Is this experiment recruiting new test subjects?
"This information can be found on clinicaltrials.gov. The trial was first advertised on 4/22/2022 and has since been edited (11/4/2022)."
How many people fit the criteria to participate in this clinical trial?
"That is correct. The clinical trial mentioned is recruiting patients, as stated on the website. This particular study was posted on 4/22/2022 and updated last on 11/4/2022; at the moment, there are 17 sites looking for a total of 250 individuals to participate."
Who else is applying?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger